OWKIN announced a new partnership with Boehringer Ingelheim to combine cutting-edge AI with multimodal data for drug discovery and development.
Public source
Publisher name
Public post
Excited to share some big news! We are proud to announce our new partnership with Boehringer Ingelheim. By combining cutting-edge AI with deep, rich multimodal data, thi…
Company
OWKIN
From token to patient impact
- Industry
- Technology, Information and Internet
- Location
- New York, US
- Company size
- 201–500 employees
About OWKIN
Owkin is the vertical patient-driven layer that turns model companies frontier intelligence into expert- and experimentally validated biomedical outcomes, creating a new biology step to AGI.
See moreLatest activity
Latest activity from OWKIN
16 signals
Products & Services
OWKIN announced the launch of Initiative W, an independent, science-led effort focused on the safe development of AI at the intersection of biology and healthcare.
Presence & Recognition
OWKIN is heading to BioTechX Europe 2026 in Basel from October 6 to 8.
People
OWKIN hired Bryan Ly as a Research Intern to work within the Drug Discovery team on generative approaches, particularly flow matching models.
Discover more
Similar signals
Similar public activity from other companies.
Partnerships
chAIron
chAIron announced a licensing agreement with Boehringer Ingelheim covering its AI research platform and patient data.
Partnerships
Boehringer Ingelheim
Boehringer Ingelheim is working with Owkin to access and generate multimodal patient data to improve disease biology understanding and support data-driven discovery across oncology and immunology.
Partnerships
Biohub
Biohub partnered with Owkin and Boehringer Ingelheim to license K Pro AI Scientist and oncology data.
Partnerships
Future4care
Future4care entered into a partnership with CRIP Pharma to address generative AI at the concret angle.
Partnerships
Lifebit